Marketing of Leading Prescription Treatments for Schizophrenia, Including RISPERDAL(R) and RISPERDAL(R) CONSTA(R)
September 19, 2005 17:10

Results from the National Institutes of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial, published in the September 22 issue of the New England Journal of Medicine, underscore that people with schizophrenia need many medication options because what works well for one patient may not work as well for another. The efficacy results for RISPERDAL? (risperidone) did not demonstrate the full efficacy of RISPERDAL? because many patients in the CATIE trial received doses that were too low(i). Further, the study highlights the need for newer therapies that can improve adherence to medication and address other unmet needs of these patients who battle this lifelong disease.